Teva Pharma Announces Launch Of Generic Symbyax In U.S.

Teva, Alexa Announce Exclusive U.S. License And Supply Deal For ADASUVE

Teva First Quarter Results Top Estimates

Teva Q1 Profit Down - Quick Facts

Teva Pharmaceutical Industries Q1 13 Earnings Conference Call At 8:00 AM ET

Trade TEVA now with

6/21/2012 1:33 PM ET

Teva Pharmaceutical Industries Ltd. (TEVA: Quote) announced the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax.

Symbyax is marketed by Lilly USA and approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults. The brand product had annual sales of about $82 million in the United States, based on IMS sales data.

Click here to receive FREE breaking news email alerts for Teva Pharmaceutical Industries Limited and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 119 Articles Next>>

Editors Pick

Stocks Nearly Flat As Early Buying Interest Fades - U.S. Commentary

After failing to sustain an early upward move, stocks have shown a lack of direction over the course of morning trading on Tuesday. The major averages have pulled back near the unchanged line after moving modestly higher in early trading.

Obama's Approval Rating Holding Steady Despite Scandals

While a recent series of scandals have caused headaches for the White House, the results of a Washington Post-ABC News poll released Tuesday suggest that the news has not had an impact on President Barack Obama's approval rating. The poll showed that 51 percent of Americans approve of the way Obama is handling his job as president compared to 44 percent that disapprove.

U.K. Inflation Eases To 7-Month Low

U.K. consumer price inflation slowed more-than-expected to a seven-month low in April on falling petrol and air fares, official data revealed Tuesday. The slowdown provides relief for consumers as it raises purchasing power, while it gives more scope for the central bank to ease monetary policy.